Fortinet's 2026 Global Threat Landscape Report reveals that AI and automation are enabling cybercriminals to exploit critical vulnerabilities within 24 to 48 hours, significantly increasing pressure on cybersecurity defenders. Doug Santos of Fortinet emphasizes that attackers are using AI across the cyber kill chain for reconnaissance, phishing, and credential harvesting, making it crucial for organizations to adopt AI-driven defenses and faster response strategies. The report highlights the growing underground market for stolen identities and infrastructure access, underscoring the need for proactive security measures.

Palo Alto Networks is set to report its third-quarter earnings, with the cybersecurity company focusing on integrating its recent acquisition, CyberArk. The company is strategically positioning itself to offer security services for artificial intelligence agents across enterprise networks, mirroring its competitor CrowdStrike's efforts in the AI security space.

This article highlights several stocks to watch on Tuesday, June 2nd, with S&P 500, Nasdaq, and Dow Jones futures trading higher. Dollar General, Palo Alto Networks, and GitLab are all set to report earnings, with analysts providing revenue and EPS expectations. Additionally, Alphabet announced plans for a large stock sale including an investment from Berkshire Hathaway for AI buildout, and Hewlett Packard Enterprise reported strong second-quarter results.

Supermicro, in collaboration with AMD, is showcasing its next-generation AMD Helios rack-scale AI platform at Computex. This 72-GPU double-width Helios rack is built on Supermicro's DCBBS architecture and features AMD Instinct MI455X GPUs, targeting large-scale AI training, inference, and LLM workloads. The platform emphasizes modular scalability, open networking, advanced security, and ROCm software integration to accelerate deployment and operational efficiency for CSPs, hyperscalers, and enterprises.

Supermicro, in collaboration with AMD, is showcasing its new AMD Helios rack-scale platform at Computex, designed to accelerate the deployment and operational efficiency of large-scale AI workloads. This 72-GPU system, powered by AMD Instinct™ MI455X GPUs and 6th Gen AMD EPYC™ CPUs, utilizes Supermicro's Data Center Building Block Solutions (DCBBS) for scalable AI infrastructure. The Helios platform aims to provide unprecedented AI performance and improved power efficiency for Cloud Service Providers, hyperscalers, and enterprises.

Frances Arnold, a director at Alphabet Inc. (NASDAQ:GOOGL), sold 102 shares of Class C Capital Stock for $38,862 on May 29, 2026, as part of a Rule 10b5-1 trading plan. Following the sale, she directly holds 18,721 shares and significant Google Stock Units. Despite the stock's strong performance, InvestingPro analysis suggests it is currently overvalued.

Microchip Technology Inc. (NASDAQ: MCHP) has announced the appointment of Mitch Little, former Senior Vice President, Worldwide Client Engagement, to its Board of Directors, effective June 1, 2026. Microchip's President and CEO, Steve Sanghi, highlighted Mr. Little's extensive experience and deep understanding of the business as key assets to the Board. Mr. Little expressed his excitement to rejoin the company and contribute to its strategic growth.

The Horizon Managed Risk ETF (SFTY), which focuses on AI, has experienced a significant surge in trading volume, increasing 33-fold compared to its average daily volume. The ETF's top holdings include major tech companies like Nvidia, Apple, Alphabet, Microsoft, and Broadcom, all of which are seeing increased attention due to the growing investments in AI and data centers. The article highlights recent developments and bullish sentiment surrounding these key companies that contribute to SFTY's performance.

Summit Therapeutics (SMMT) stock slid by 7.67% following investor concerns over recent clinical development news, including downgrades from H.C. Wainwright and Bernstein. Analysts cited limited overall survival data from a key trial, skepticism about future catalysts, and weak fundamentals, leading to bearish ratings and a low price target. Furthermore, a shareholder-rights probe by Johnson Fistel initiated after a post-earnings drop added to the negative sentiment surrounding the clinical-stage biotech company.

Vaxcyte Inc, a US-based vaccine developer (PCVX), reported a wider-than-expected net loss of USD -2.30 per share for Q1 2026, exceeding analyst expectations of USD -1.74. The company's Q1 results and pipeline progress are being closely watched by investors, especially with the next estimated earnings date in early August for Q2 2026. As a clinical-stage company, Vaxcyte's expenses for research and development continue to outweigh revenues, highlighting the cost-intensive nature of vaccine development.